By Fineline Cube 
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its in-house developed adjuvanted influenza split vaccine, BK-01.
Vaccine Profile
The BK-01 adjuvanted vaccine targets individuals aged 60 and above. It is designed to stimulate the body to produce a stronger immune response after inoculation, aiding in the prevention of influenza caused by the influenza virus.
Technical Advantages
Based on influenza split-virion technology paired with a proprietary adjuvant, BK-01 maintains a favorable vaccine safety profile. It demonstrates superior immunogenicity compared to conventional split vaccines and generates higher levels of protective antibodies.-Fineline Info & Tech